Selling, General, and Administrative Costs: Sanofi vs Bio-Techne Corporation

Sanofi vs Bio-Techne: A Decade of SG&A Expense Trends

__timestampBio-Techne CorporationSanofi
Wednesday, January 1, 2014607160008565000000
Thursday, January 1, 20151194010009496000000
Friday, January 1, 20161408790009592000000
Sunday, January 1, 201719924300010164000000
Monday, January 1, 20182406360009934000000
Tuesday, January 1, 20192643590009883000000
Wednesday, January 1, 20202605830009390000000
Friday, January 1, 20213249510009555000000
Saturday, January 1, 202237276600010539000000
Sunday, January 1, 202337837800010765000000
Monday, January 1, 20243968260009183000000
Loading chart...

In pursuit of knowledge

A Comparative Analysis of SG&A Expenses: Sanofi vs Bio-Techne Corporation

In the ever-evolving landscape of the pharmaceutical and biotechnology sectors, understanding the financial dynamics of industry giants is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Sanofi and Bio-Techne Corporation from 2014 to 2023. Over this period, Sanofi's SG&A expenses have consistently dwarfed those of Bio-Techne, reflecting its expansive global operations. In 2023, Sanofi's expenses peaked at approximately $10.8 billion, marking a 26% increase from 2014. In contrast, Bio-Techne's expenses grew by an impressive 554%, reaching nearly $397 million in 2024. This stark contrast highlights the differing scales and growth trajectories of these companies. Notably, the data for 2024 is incomplete for Sanofi, indicating potential shifts in financial strategies. As these companies navigate the complexities of the healthcare market, their SG&A trends offer valuable insights into their operational priorities and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025